Menu
Washingtoner
  • Home
  • Health
  • Artificial Intelligence
  • Technology
  • Entertainment
  • Software
  • Real Estate
  • Business
  • Education
Washingtoner

Study Finds Lotus Vaping Technologies' Flavored E-Liquids Reduce Smokers' Cigarettes Per Day at Significantly Higher Rate Than Tobacco Flavor
Washingtoner/10239600

Trending...
  • ThriveStack citedby launches Prompt Research to find the prompts buyers ask in AI search
  • Global Leaders Convene in Seattle to Advance Responsible AI and Cross-Border Ecosystems
  • Haven Treatment Center Pays It Forward with Donation of 150 Food Boxes and Gift Cards to Evergreen
A rigorous three-month longitudinal cohort study of several of flavored bottled e-liquids demonstrated that those flavors were significantly more effective at reducing cigarettes smoked per day than tobacco-flavored e-liquids.

BOISE, Idaho - Washingtoner -- Lotus Vaping Technologies, LLC, a Boise, Idaho-based manufacturer of bottled e-liquids for use in electronic nicotine delivery systems ("ENDS") or e-cigarettes, announced today that a rigorous three-month longitudinal cohort study of several of its FreenomsTM branded flavored bottled e-liquids demonstrated that those flavors were significantly more effective at reducing cigarettes smoked per day than tobacco-flavored e-liquids.

The three-month study conducted from March 2023 to August 2023 involved 451 randomly assigned participants who were cigarette smokers, 221 of which were assigned to a control group that used only tobacco-flavored e-liquid, and 230 of which were assigned to a group that could use any of five different non-tobacco flavored bottled e-liquids, including Lotus's proprietary BluenomenomTM, StranomenonTM, X2 Cactus Jackfruit, and White Peach Raspberry flavors.

More on Washingtoner
  • The Villari Firm, PLLC Named to the 2027 Edition of Best Law Firms
  • Spokane: City and County Issue Joint Housing and Homelessness Funding RFP
  • Spokane: Council Approves Additional Funding to Prepare for Inclement Weather
  • Bacchus Wine & Spirits and Michelin Guide–Recommended Ethel's Fancy to Host Exclusive LOUIS XIII Limited Edition Diwali Decanter Celebration
  • Arizona Pest Control Surpasses $200,000 in Contributions to Southern Arizona High School Sports and Education Programs

At the end of three months, the average number of cigarettes smoked per day ("CPD") by the tobacco-flavored control group was reduced from 12.51 to 9.54, for a 23.72% reduction, while for the flavored e-liquid group, the average CPD was reduced from 11.70 to 6.88, for a 41.25% reduction.  The reduction in cigarettes smoked per day was thus 73.9% greater for the flavored group than the tobacco-flavored group. The study results also demonstrated statistically significant differences between several of Lotus's flavored e-liquids when compared head-to-head against tobacco-flavored e-liquids with respect to CPD reduction.

Additionally, a full 14.3% of study participants in the flavored group had quit smoking cigarettes altogether by the end of the third month—a rate that is substantially higher than that typically reported for FDA-approved nicotine replacement therapy products (9.0%).

Lotus's Director of Sales, Mike Larsen stated, "We are very excited about these study results. This study demonstrates what users of our products have known anecdotally for a long time—flavored e-liquids are more effective than tobacco flavor at promoting cigarette smoking reduction and cessation. The FDA has been asking for this data—we hope it will now take it into consideration when reviewing our premarket tobacco product applications and grant our flavored products the marketing authorizations that they deserve."

More on Washingtoner
  • ZenaTech (NAS DAQ: ZENA) $1 Million in New Utility Contracts- Potential $2.5 Million Follow-On Opportunity Puts Its Drone Business in the Spotlight!
  • New Patient Data Show REQORSA® Activating Cellular Repair Pathways as Roche Collaboration Advances Precision Lung Cancer Strategy for Genprex, Inc
  • Genuine Hospitality, LLC Selected to Operate Holiday Inn Express & Suites Jacksonville – Town Center
  • Shiokly Launches Online Marketplace to Help Singapore Home-Based Businesses Sell More, With First Product Listed Free
  • Freight Broker 911 and Milton Collier Introduce "What's The 911?"—A New Podcast Built on Real Talk, Real Freight, and Real Opportunity

About Lotus Vaping Technologies, LLC – Creator of NomenonsTM E-Liquids

Established in 2013, Lotus is a leading manufacturer and wholesaler of premium e-liquids in the United States providing a diverse range of vapor products for sale to adult consumers that satisfy a wide variety of consumer preferences and serve as alternatives to combustible cigarettes. Lotus is committed to responsible manufacturing processes and utilizes only the highest standards in its e-liquid production.

Media Contact
Mike Larsen
mike@lotusecigs.com


Source: Lotus Vaping Technologies, LLC
Filed Under: Health

Show All News | Disclaimer | Report Violation

0 Comments
1000 characters max.

Latest on Washingtoner
  • Building a Technology Powerhouse-From AI Drones and Global Acquisitions to Defense, Enterprise Software and the Future of Autonomous Operations $ZENA
  • Shelter Structures America backs MATRA Second Life Project to turn retired tent vinyl into homes for displaced families
  • P-Wave Press Announces Becoming Dad: Reflections for New Fathers by L. A. Davenport
  • Logicraft Launches FuelDeck™, AI That Turns Aviation Fuel Tickets Into One Traceable Ledger
  • Inaugural OC Tech Week Draws 3,000 From 12 Countries, Sends Finalist to $1M Startup World Cup
  • Award-Winning American Hotelier Opens Art-Filled Luxury Cottage in Norfolk, England
  • K2 Global / Ozi Amanat Named Among Top 100 AI Venture Capitalists in 2026
  • Community Days at Spokane City Council Celebrating Veteran's Day
  • Dr. Latorial Faison Appointed Poet Laureate of Virginia
  • Sparta Services Named to CRN's 2026 AI Innovators List
  • AdLeverage Brings Golf Simulator Contest and Home Services Marketing Expertise to Service World Expo 2026
  • Cleveland Factory Worker Seeks Funding for AI-Readable Archive Exploring Advanced AI Restraint and Human Survival
  • TradeJARnal Launches Innovative Trading Journal to Help Stock and Options Traders Build Discipline and Smarter Trading Habits
  • Pursant Founder Mark Herbick Joins STS Capital Partners as CEO
  • HiLine Homes' "Building Homes & Filling Plates" Food Drive Returns to Support Local Families
  • Tampa Holiday Sessions: Captured by Mallary Opens 2026 Christmas Minis With Two New Sets
  • Tampa Web Design Launches New Website for Entrepreneur and Capital Markets Advisor Martin Sumichrast
  • Miami Dade College and World Affairs Council of Miami announce Navarro-Cabrera scholarship
  • RPP to host first Professional Padel Week in Miami and announce the 2026 USA Awards winners
  • UK Financial Ltd. Announces Maya Preferred PRA as First Fully Verified Asset on MAYA CHAIN; Chainlink Proof of Reserve Integration Planned for Network
_catLbl0 _catLbl1

Popular on Washingtoner

  • Spokane: City and Permittable Partner to Support Rebuilding After Wildfires - 303
  • Spokane: City to provide asbestos testing, host community resource meetings - 251
  • Tacoma: In-Person Workshop on October 22 for Local Businesses on the City’s Revolving Loan Fund Process - 210
  • Pre-Seed VC Martin Tobias Makes Fundraising Tool Available to Every Startup CEO as Investor Match - 179
  • Final Week to Register for Free Spokane Community Conference - 150
  • Citizens for West Virginia Election Integrity Urges "FOR" on Amendment 1 - 145
  • New Research Spotlight, Expanding TUSC2 Science & Strategic Development Milestones Put Gene Therapy Innovation into Focus for Genprex (NAS DAQ: GNPX) - 144
  • Geospatial Innovation Comes to Sacramento: FOSS4G NA 2026 - 114
  • Holiday Gambling Spending Expected to Rise 12% in December - 111
  • Author Robert A. Robinson Introduces Anarchy at the AYP: - 110

Similar on Washingtoner

  • OncoBeta Introduces Rhenium-SCT for Non-Melanoma Skin Cancer at Theageneio Cancer Hospital of Thessaloniki
  • New Patient Data Show REQORSA® Activating Cellular Repair Pathways as Roche Collaboration Advances Precision Lung Cancer Strategy for Genprex, Inc
  • New TROP2 Research Breakthrough Strengthens REQORSA® Gene Therapy Story as Roche Collaboration Advances Precision Lung Cancer Treatment: Genprex, Inc
  • FDA Approval; Major Milestone for Preservative-Free Ketamine Ahead of FDA Goal Date for Treatment of Suicidal Depression by NRx Pharmaceuticals, Inc
  • Haven Treatment Center Pays It Forward with Donation of 150 Food Boxes and Gift Cards to Evergreen
  • Major FDA Victory; Preservative-Free Ketamine Approved Ahead of November 10 Goal Date as Commercial Launch Opportunity Comes Into Focus for NRx Pharma
  • New Research Spotlight, Expanding TUSC2 Science & Strategic Development Milestones Put Gene Therapy Innovation into Focus for Genprex (NAS DAQ: GNPX)
  • Paraguay Expedition Offers a Different View of Human Resilience
  • Longevity Academy Features Gail Humble, MD of KLOTHO SKIN in the Longevity Leaders Project
  • Expanding Into Medically Supervised Wellness With Major Apollo Wellness Centers Announcement; Sibannac, Inc. (Stock Symbol: SNNC)
Copyright © 2026 washingtoner.com | Terms of Service | Privacy Policy | Contact Us | Contribute